TY - JOUR
T1 - The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma
T2 - A Cross-analysis of a Population-based Registry and a Tertiary Care Center
AU - Evans, Laura A.
AU - Go, Ronald
AU - Warsame, Rahma
AU - Nandakumar, Bharat
AU - Buadi, Francis K.
AU - Dispenzieri, Angela
AU - Dingli, David
AU - Lacy, Martha Q.
AU - Hayman, Suzanne R.
AU - Kapoor, Prashant
AU - Leung, Nelson
AU - Fonder, Amie
AU - Hobbs, Miriam
AU - Hwa, Yi Lisa
AU - Muchtar, Eli
AU - Kourelis, Taxiarchis V.
AU - Russell, Stephen
AU - Lust, John A.
AU - Lin, Yi
AU - Siddiqui, Mustaqeem
AU - Kyle, Robert A.
AU - Gertz, Morie A.
AU - Rajkumar, S. Vincent
AU - Kumar, Shaji
AU - Gonsalves, Wilson I.
N1 - Funding Information:
Research reported in this publication was supported by the Mayo Clinic Hematological Malignancies Program and in part by grants from the National Cancer Institute of the National Institutes of Health under Award Number CA254961. It is also supported in part by the CTSA Grant UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Finally, this research is also supported in part by the Marion Schwartz Foundation for Multiple Myeloma .
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/7
Y1 - 2021/7
N2 - Background: Multiple myeloma (MM) is a heterogeneous clonal plasma cell disorder leading to differences in clinical outcomes such as overall survival (OS) among patients. We hypothesized that with expensive, novel therapeutic agents and paradigm shifts to maintain continuous therapy and improvement in OS, patients with MM are subject to the pressures of financial toxicity and the need for social support, which may be of prognostic importance. Materials and Methods: In this study, we examined the records of 122,458 patients from the National Cancer Database (NCDB) to determine the significance of socioeconomic factors such as estimated annual household income and education level, which were based on the patient's ZIP Code and the United States Census Bureau's 5-year report from 2008 to 2012. These socioeconomic factors, in addition to marital status, were then assessed individually and as a cumulative socioeconomic score for prognostic significance in a cohort of 2543 patients treated at a tertiary care center utilizing known biologic risk factors, such as cytogenetic risk, International Staging System classification, and serum lactate dehydrogenase levels. Results: Only marital status and estimated annual household income at diagnosis negatively impacted OS in a univariate analysis, but not in the context of a multivariable analysis incorporating known biologic risk factors. Conclusion: Future analyses in other academic and non-academic centers located in urban and rural regions are required to understand the socioeconomic drivers of OS disparity among patients with MM observed nationally.
AB - Background: Multiple myeloma (MM) is a heterogeneous clonal plasma cell disorder leading to differences in clinical outcomes such as overall survival (OS) among patients. We hypothesized that with expensive, novel therapeutic agents and paradigm shifts to maintain continuous therapy and improvement in OS, patients with MM are subject to the pressures of financial toxicity and the need for social support, which may be of prognostic importance. Materials and Methods: In this study, we examined the records of 122,458 patients from the National Cancer Database (NCDB) to determine the significance of socioeconomic factors such as estimated annual household income and education level, which were based on the patient's ZIP Code and the United States Census Bureau's 5-year report from 2008 to 2012. These socioeconomic factors, in addition to marital status, were then assessed individually and as a cumulative socioeconomic score for prognostic significance in a cohort of 2543 patients treated at a tertiary care center utilizing known biologic risk factors, such as cytogenetic risk, International Staging System classification, and serum lactate dehydrogenase levels. Results: Only marital status and estimated annual household income at diagnosis negatively impacted OS in a univariate analysis, but not in the context of a multivariable analysis incorporating known biologic risk factors. Conclusion: Future analyses in other academic and non-academic centers located in urban and rural regions are required to understand the socioeconomic drivers of OS disparity among patients with MM observed nationally.
KW - Myeloma
KW - Outcomes
KW - Prognosis
KW - Socioeconomic status
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=85103311797&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103311797&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2021.02.001
DO - 10.1016/j.clml.2021.02.001
M3 - Article
C2 - 33785296
AN - SCOPUS:85103311797
SN - 2152-2650
VL - 21
SP - 451-460.e2
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 7
ER -